论文部分内容阅读
目的 探索ELFP方案治疗转移复发的晚期鼻咽癌、食管癌、胃癌的临床疗效和毒性。方法 选择病理证实的 6 4例晚期鼻咽癌、食管癌、胃癌采用Vp - 16 0 .1g静滴 ,d1～ 3 ;CF 0 .1g静滴 ,d1～ 3 5 -FU 0 .5g静滴 ,d1～ 3 ;DDP 5 0mg静滴 ,d1～ 2 ;2 1d为 1周期。治疗 2～ 6个周期。结果 鼻咽癌 ,食管癌、胃癌有效率 (CR +PR)分别为 75 %、70 %、4 3.8% ,其中胃癌与鼻咽癌及食管癌分别比较有差异 ;单病灶与多病灶之间疗效无差异。全组病例总生存期为 3～ 4 1月 ,中位生存期分别为 11.5、10、7.5个月。主要毒性为骨髓抑制 ,其中Ⅲ、Ⅳ度白细胞下降占 2 1.9% ;Ⅲ、Ⅳ度血红蛋白下降占 15 .6 % ;Ⅲ、Ⅳ度血小板下降占 3.1%。Ⅲ、Ⅳ度恶心、呕吐发生率为 7.8%。结论 ELFP对晚期鼻咽癌及食管癌有较好的疗效 ,其毒性可以耐受 ,是临床治疗鼻咽癌 ,食管癌切实可行的方案。
Objective To explore the clinical efficacy and toxicity of ELFP regimen in the treatment of advanced nasopharyngeal carcinoma, esophageal carcinoma and gastric carcinoma with metastasis and recurrence. Methods Sixty-four cases of advanced nasopharyngeal carcinoma, esophageal carcinoma and gastric carcinoma confirmed by pathology were selected with intravenous infusion of Vp -160.1g, d1-3, CF0.1g, d1-3.5 -FU0.5g intravenously, d1 ~ 3; DDP 5 0mg intravenous infusion, d1 ~ 2; 2 1d for 1 cycle. Treatment of 2 to 6 cycles. Results The effective rate (CR + PR) of nasopharyngeal carcinoma, esophageal carcinoma and gastric carcinoma were 75%, 70% and 43.8%, respectively. There were differences between gastric carcinoma and nasopharyngeal carcinoma and esophageal carcinoma respectively. The single and multiple lesions No difference. The overall survival of patients was 3 ~ 4 January, the median survival were 11.5,10,7.5 months. The main toxicity was myelosuppression, in which Ⅲ, Ⅳ leukopenia accounted for 2 1.9%; Ⅲ, Ⅳ hemoglobin decreased 15.6%; Ⅲ, Ⅳ degree of thrombocytopenia 3.1%. Ⅲ, Ⅳ degree of nausea, vomiting was 7.8%. Conclusion ELFP has good curative effect on advanced nasopharyngeal carcinoma and esophageal carcinoma and its toxicity can be tolerated. It is a feasible solution for clinical treatment of nasopharyngeal carcinoma and esophageal carcinoma.